<code id='79AA647D84'></code><style id='79AA647D84'></style>
    • <acronym id='79AA647D84'></acronym>
      <center id='79AA647D84'><center id='79AA647D84'><tfoot id='79AA647D84'></tfoot></center><abbr id='79AA647D84'><dir id='79AA647D84'><tfoot id='79AA647D84'></tfoot><noframes id='79AA647D84'>

    • <optgroup id='79AA647D84'><strike id='79AA647D84'><sup id='79AA647D84'></sup></strike><code id='79AA647D84'></code></optgroup>
        1. <b id='79AA647D84'><label id='79AA647D84'><select id='79AA647D84'><dt id='79AA647D84'><span id='79AA647D84'></span></dt></select></label></b><u id='79AA647D84'></u>
          <i id='79AA647D84'><strike id='79AA647D84'><tt id='79AA647D84'><pre id='79AA647D84'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:focus    Page View:297
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In